

Edgar Filing: APPIANT TECHNOLOGIES INC - Form SC 13D/A

APPIANT TECHNOLOGIES INC  
Form SC 13D/A  
June 22, 2001

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13D  
(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO  
RULE 13d-2(a)

(Amendment No. 6 ) (1)

Appiant Technologies, Inc.  
(f/k/a Nhancement Technologies, Inc.)

-----  
(Name of Issuer)

Common Stock, \$.01 par value

-----  
(Title of Class of Securities)

03782R108

-----  
(CUSIP Number)

Gerald L. Fishman  
Wolin & Rosen, Ltd.  
55 West Monroe Street, Suite 3600  
Chicago, IL 60603  
312.424.0600

-----  
(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)

July 31, 2000

-----  
(Date of Event which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box .

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

- 
- (1) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be

Edgar Filing: APPIANT TECHNOLOGIES INC - Form SC 13D/A

deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(SC13D-07/99)

(Continued on following pages)  
(Page 1 of 7 Pages)

CUSIP No. 03782R108

13D

Page 2 of 7 Pages

---

1 NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

L. Thomas Baldwin III SS No.  
L. Thomas Baldwin III Living Trust u/t/a dated 11/9/95 FEIN No.

---

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a)  [X]  
(b)  [ ]

See Note A

---

3 SEC USE ONLY

---

4 SOURCE OF FUNDS\*

PF -- See Note A

---

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED  
PURSUANT TO ITEMS 2(d) OR 2(e)

Item 2(d)  [ ]  
Item 2(e)  [ ]

---

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Illinois

---

7 SOLE VOTING POWER

NUMBER OF 3,237,675 See Note A  
SHARES

---

8 SHARED VOTING POWER

BENEFICIALLY 586,490 See Note A  
OWNED BY

---

9 SOLE DISPOSITIVE POWER

EACH 3,237,675 See Note A  
REPORTING

---

10 SHARED DISPOSITIVE POWER

PERSON 586,490 See Note A  
WITH

Edgar Filing: APPIANT TECHNOLOGIES INC - Form SC 13D/A

CUSIP No. 03782R108

13D

Page 3 of 7 Pages

---

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

3,086,245 -- L. Thomas Baldwin III (See Note A)  
151,430 -- L. Thomas Baldwin III Living Trust (See Note A)

---

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\*

[X]  
See Note A

---

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

25.2%

---

14 TYPE OF REPORTING PERSON\*

IN -- L. Thomas Baldwin III  
OO -- L. Thomas Baldwin III Living Trust

---

\*SEE INSTRUCTIONS BEFORE FILLING OUT!

ITEM 1. SECURITY AND ISSUER

- a. Appiant Technologies, Inc.  
(f/k/a Nhancement Technologies, Inc.)  
6663 Owens Drive  
Pleasanton, CA 94588
- b. Common Stock, \$.01 par value

ITEM 2. IDENTITY AND BACKGROUND

- |                                                                  |                                                                       |
|------------------------------------------------------------------|-----------------------------------------------------------------------|
| a. L. Thomas Baldwin III                                         | a. L. Thomas Baldwin III Living Trust, L. Thomas Baldwin III, Trustee |
| b. 141 West Jackson Boulevard<br>Suite 2850<br>Chicago, IL 60604 | b. 141 West Jackson Boulevard<br>Suite 2850<br>Chicago, IL 60604      |
| c. Investor, Trader                                              | c. Trust, Trustee                                                     |
| d. N/A                                                           | d. N/A                                                                |
| e. N/A                                                           | e. N/A                                                                |
| f. USA                                                           | f. Illinois, USA                                                      |

ITEM 3. SOURCE AND AMOUNT OF FUNDS FOR OTHER CONSIDERATION

## Edgar Filing: APPIANT TECHNOLOGIES INC - Form SC 13D/A

The source of the funds are the personal funds of L. Thomas Baldwin III and the L. Thomas Baldwin III Living Trust. The aggregate amount of funds used in making purchases through and including 31 March 2001 for these Reporting Persons (see Note A) were \$49,962,198 for Mr. Baldwin and \$2,645,036 for the L. Thomas Baldwin III Living Trust.

CUSIP No. 03782R108

13D

Page 4 of 7 Pages

### ITEM 4. PURPOSE OF TRANSACTION

The purpose of the acquisition of securities of the Issuer is as an investment by L. Thomas Baldwin III.

- a. Mr. Baldwin has no present plans to purchase additional shares of the Issuer except as a result of possible conversion or exercise of convertible securities or warrants currently held by him.
- b-j. Mr. Baldwin has no present intentions to engage in or cause any of the matters listed in these subsections of this Item 4. His present intention is to be and remain an investor in the Issuer. In December, 2000, Mr. Baldwin was elected a director of the Issuer. The timing and amount of additional purchases, if any, are currently unknown.

### ITEM 5. INTEREST AND SECURITIES OF THE ISSUER

#### a. Shares owned:

- (1) L. Thomas Baldwin III -- 3,237,675 shares (25.2%)  
(See Note A)
  - (2) Rosenthal Collins Group, L.L.C. (See Note A)
    - (i) L. Thomas Baldwin III -- 435,060 shares (3.4%)
    - (ii) L. Thomas Baldwin III Living Trust -- 151,430 shares (1.2%)
- Total Rosenthal Collins Group, L.L.C. -- 586,490 shares (4.6%)
- Total Group (See Note A) -- 3,824,165 shares (29.8%)

#### b. Voting power:

- (1) L. Thomas Baldwin III, individually (See Note A)
  - Sole voting power -- 3,237,675
  - Shared voting power --- 586,490
  - Sole dispositive power -- 3,237,675
  - Shared dispositive power -- 586,490
- (2) Rosenthal Collins Group, L.L.C. (See Note A)
  - Sole voting power -- 586,490
  - Shared voting power --- 586,490
  - Sole dispositive power -- 586,490
  - Shared dispositive power -- 586,490

- c. In connection with its \$2,500,000 Convertible Promissory Note issued to this Reporting Person, the Issuer agreed to issue this Reporting Person a Warrant to purchase 462,963 shares of the Issuer's Common Stock, subject to adjustment and to the issuance of additional Warrants if the Issuer does not receive certain additional equity investments. All such Warrants are exercisable immediately at an exercise price of \$2.70 per share (subject to adjustment pursuant to the terms of the Warrants) and expire 7 years from issuance.

On May 31 2001, this Reporting Person purchased at par, the Issuer's \$150,000 face amount Convertible Promissory Note ("Promissory Note") due and payable on June 21, 2001, ("Maturity Date"). The number of shares into which the Promissory Note may be converted on the Maturity Date is equal to the amount due under the Promissory Note divided by a conversion price determined by taking 90% of the exercise or conversion price (or exchange factor) applicable to any security comprising any interim financing subsequent to the date of the Promissory Note ("Interim Financing") which is exercisable or convertible into or exchangeable for the Issuer's Common Stock. If there is no Interim Financing on or before the Maturity Date, then this Reporting Person may choose to convert the amount due from the Issuer into shares at 90% of the closing price of the Issuer's Common Stock on the trading day immediately preceding the Maturity Date.

In further consideration for the Promissory Note, this Reporting Person is to receive a warrant to purchase 30,000 shares of the Issuer's Common Stock, exercisable immediately, at an exercise price of \$1.57 per share. The Issuer has agreed to register the shares issuable upon exercise in its next registration of shares.

d. N/A

e. N/A

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

See Note A with respect to the relationships among the persons named in Item 2 and with respect to the securities of the Issuer.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

1. There are no materials relating to the borrowing of funds to finance the acquisition, as disclosed in Item 3.

2. There are no written agreements relating to the acquisition of Issuer control, liquidation, sale of assets, merger or change in business or corporate structure or any other matter, as

Edgar Filing: APPIANT TECHNOLOGIES INC - Form SC 13D/A

disclosed in Item 4.

3. There are no written agreements relating to the transfer of voting of the securities, finders' fees, joint ventures, options, puts, calls, guarantees of loans, guarantees against loss of profit, or the giving or withholding of any proxy, as disclosed in Item 6, except the Common Stock Warrant attached as an Exhibit hereto.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: June 22, 2001.

/s/ L. Thomas Baldwin III

-----  
L. THOMAS BALDWIN III,  
Individually and as Trustee of  
the L. Thomas Baldwin III Living  
Trust u/t/a dated 11/9/95

Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).

NOTE A

This Schedule 13D represents ownership by the Reporting Person and other members of the "group" as described below of an aggregate of 3,824,165 shares of common stock of the Issuer (29.8%), including immediately exercisable warrants to purchase 300,000 shares at \$6.00 per share and 30,000 shares at \$1.57 per share, but excluding (i) shares issuable upon conversion of a \$2,500,000 Convertible Promissory Note and a Warrant to purchase 462,963 shares (as may be adjusted) (not more than 19.9% without shareholder approval) and (ii) shares issuable upon conversion of a \$150,000 Convertible Promissory Note, all as described in Item 5c above. L. Thomas Baldwin III is a non-voting, non-managing member of Rosenthal Collins Group, L.L.C., an Illinois limited liability company ("RCG"). RCG is registered with the Commodity Futures Trading Commission as a futures commission merchant and is a clearing member of all major principal futures exchanges in the United States and elsewhere. As such, RCG is required to meet and maintain significant levels of adjusted net capital to comply with CFTC and exchange clearing requirements.

While RCG has full legal control over 586,490 shares, Mr. Baldwin could always direct RCG to sell the shares, which accommodation RCG would be willing to accommodate subject, of course, to all the various capital requirements with which RCG must comply. Moreover, as an accommodation, RCG would be willing to defer to Mr. Baldwin with respect to the voting of such shares. Hence, RCG in Item 5.b has listed the shares deposited with it as owned by it, and it has listed voting and dispositive power as shared with Mr. Baldwin.

CUSIP No. 03782R108

13D

Page 7 of 7 Pages

While the shares of the Issuer held by RCG are owned of record and are under its total legal control, RCG, solely for purposes of the shares of the Issuer and

**Edgar Filing: APPIANT TECHNOLOGIES INC - Form SC 13D/A**

not otherwise, should be deemed an affiliate of L. Thomas Baldwin III and Mr. Baldwin should be deemed de facto beneficial owner of all such shares, notwithstanding that all such shares are subject to the risks and requirements, regulatory and market, of RCG.